Erlotinib-KIMOTAR®

Erlotinib-KIMOTAR®
Product Description

  • Erlotinib blocks the epidermal growth factor receptor’s tyrosine kinase to suppress tumor cell growth.
  • Validated efficacy in non-small cell lung cancer (first-line).
  • Offered in tablet form to facilitate patient-friendly, outpatient treatment.
  • Underpinned by a wide range of peer-reviewed studies confirming its clinical value.
  • Side effects are well-documented and manageable under standard clinical protocols.

    • Read more Show less

    EXAMON Handelsges.m.b.H.

    • Country/Region:
      Austria
    • On CPHI since:
      2024
    • Certificates:
      3
    • Employees:
      100 - 249
    Company types
    Generics/Biosimilars Manufacturer
    Pharmaceutical company
    Primary activities
    API Producer
    Generic APIs producer
    Pharmaceutical Company (generic finished products)
    View company profile
    Categories
    more categories Show less
    Specifications
    • Details
       Oral film-coated tablet: 150 mg
    • Selling Points

      • Oral Formulation
      • Affordability
      • Proven Impact
      • Stringent Quality

    • Model
      150 mg
    More specifications Fewer specifications

    EXAMON Handelsges.m.b.H.

    • Country/Region:
      Austria
    • On CPHI since:
      2024
    • Certificates:
      3
    • Employees:
      100 - 249
    Company types
    Generics/Biosimilars Manufacturer
    Pharmaceutical company
    Primary activities
    API Producer
    Generic APIs producer
    Pharmaceutical Company (generic finished products)
    View company profile

    More Products from EXAMON Handelsges.m.b.H. (2)

    • Imatinib

      Product Imatinib

      • Targeted mechanism that selectively inhibits the BCR-ABL tyrosine kinase to disrupt signaling pathways driving abnormal cell growth in chronic myelogenous leukemia and gastrointestinal stromal tumors (first-line). • Clinically established with robust trials confirming its ability to control disease pro...
    • Gefitinib-GEFISA®

      Product Gefitinib-GEFISA®

      • Used for non-small cell lung cancer (NSCLC) as first-line therapy. Targets EGFR mutations to inhibit tumor growth. •  An EGFR tyrosine kinase inhibition which interrupts receptor signaling to limit tumor cell proliferation. • Robust clinical studies confirm benefits in non-small cell lung and pan...